PTC Inc.

14 hours ago · prnewswire.com

– Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease.

6 days ago · prnewswire.com

Standardizes on Creo CAD and Windchill PLM across multiple business units and locations Supports design consistency, configuration control, and traceability for complex defense programs Supports both near‑term operational needs and long‑term growth BOSTON, Sept. 15, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that Fisica Applied Technologies, Inc., a leading defense products manufacturer of airborne and ground-based antennas; electromagnetic systems and simulators; and ruggedized batteries, has selected the PTC Creo® computer-aided design (CAD) and Windchill® product lifecycle management (PLM) solutions for product design and development across its engineering environment.

13 days ago · seekingalpha.com

PTC Inc. (PTC) Presents at Citi's 2026 Global TMT Conference Transcript

25 days ago · zacks.com

PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?

26 days ago · prnewswire.com

WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Wells Fargo 21st Annual Healthcare Conference Thursday, Sept.

29 days ago · prnewswire.com

– 17 abstracts and presentations planned at SSIEM Symposium – – Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels – – Continued evidence of meaningful benefit across all patient subgroups – WARREN, N.J., Aug. 24, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that multiple Sephience™ (sepiapterin) scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, taking place in Helsinki, Finland, from Aug. 25-28.

29 days ago · seekingalpha.com

PTC Therapeutics offers a compelling risk-reward profile, with its valuation not fully reflecting the upside from Sephience and potential ST-920 approval. Sephience, PTCT's lead asset, has driven rapid revenue growth, accounting for 63% of product revenue and expanding across major global markets. ST-920, acquired from Sangamo, is a late-stage gene therapy for Fabry Disease; FDA approval could significantly enhance PTCT's valuation.

1 month ago · benzinga.com

PTC Therapeutics Inc. (NASDAQ:PTCT) on Wednesday said it is expanding its rare disease portfolio through the planned acquisition of the ST-920 Fabry disease program from Sangamo Therapeutics in a competitive bankruptcy auction.

1 month ago · prnewswire.com

Enables engineers to create reusable custom CAD features using natural language and AI, no programming experience required Automates feature development through AI-assisted building, testing, debugging, and refinement   Captures engineering knowledge as reusable CAD automation that can be shared across teams without ongoing AI interactions or recurring costs BOSTON, Aug. 13, 2026 /PRNewswire/ -- PTC  (NASDAQ: PTC) today announced the availability of the new FeatureScript™ MCP Server capability in its Onshape® CAD and PDM platform. Available through its Onshape Labs™ initiative, the capability enables engineers to create custom CAD features using natural language and AI.

1 month ago · prnewswire.com

– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization – – ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile – – BLA submission expected to be completed in Q4 2026 with potential for commercial launch in 2027 – – PTC will host a conference call today, Aug. 12, at 5 p.m. ET – WARREN, N.J.